RxDoctor Payments DataLook up a doctor →

Michael di Giovanna, DO

Internal Medicine · North Massapequa, NYNPI 1043222755

Payments from drug & device makers

$1,348,894in general payments, 2019–2025

Across 1,035 payments — averaging $1303.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$723K
  • Pfizer$154K
  • Bristol Myers Squibb$103K
  • Takeda Pharmaceuticals U.S.A., Inc.$63K
  • Biohaven Pharmaceutical Holding Company Ltd.$53K
  • Janssen Research & Development, LLC$40K
  • plus $211K from 54 others
$18,619in research payments, 2019–2025

Across 12 payments — averaging $1551.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Celltrion, Inc.$18K
  • Teva Pharmaceuticals USA, Inc.$355
  • AbbVie$264

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)181$723,132
Pfizer89$154,468
Bristol Myers Squibb12$103,411
Takeda Pharmaceuticals U.S.A., Inc.37$63,425
Biohaven Pharmaceutical Holding Company Ltd.29$53,028
Janssen Research & Development, LLC18$40,405
Teva Pharmaceuticals USA, Inc.12$34,891
Novo Nordisk AS10$31,143
AstraZeneca78$30,620
GRT US Holding, Inc.4$27,221
Novartis37$21,692
Sanofi US Services Inc.2$13,300
Sanofi-aventis U.S. LLC65$11,929
Amarin Pharma, Inc.9$9,199
Lilly USA, LLC87$6,145
Amgen77$5,488
Eli Lilly2$4,875
Astrazeneca AB2$3,542
Celltrion, Inc.1$1,597
Novo Nordisk53$1,538
Novartis Pharma AG1$1,484
Astrazeneca UK Limited5$1,200
GSK36$728
Boehringer Ingelheim26$532
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC27$457
Inspire Medical Systems, Inc.5$429
Merck22$379
Bayer17$349
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$198
Esperion Therapeutics, Inc.4$185
Sanofi Pasteur Inc.8$153
Intuity Medical Inc2$141
Biohaven Pharmaceuticals, Inc.3$125
Abbott6$122
Sumitomo Pharma America, Inc.5$120
Daiichi Sankyo Inc.6$115
Johnson & Johnson(2 entities)5$110
Astellas Pharma US Inc6$108
AVEO Pharmaceuticals, Inc.2$93
Idorsia Pharmaceuticals US Inc5$80
Otsuka America Pharmaceutical, Inc.3$70
Sanofi3$66
Genentech USA, Inc.4$65
Regeneron Healthcare Solutions, Inc.4$55
Redhill Biopharma Inc.2$49
Exact Sciences2$47
Acerus Pharmaceuticals Corporation2$31
Corcept Therapeutics1$31
Bioxcel Therapeutics, Inc.1$28
Shield Therapeutics Inc1$26
Avanir Pharmaceuticals, Inc.1$25
Dexcom, Inc.1$25
Hikma Pharmaceuticals USA1$24
Radius Health, Inc.1$23
Scilex Pharmaceuticals Inc.1$23
Linus Health, Inc.1$22
Intra-sana Laboratories1$20
E.r. Squibb & Sons, L.L.C.1$17
Arbor Pharmaceuticals, Inc.1$16
Neotract Inc.1$16

How this compares

$1,348,894 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York →

Medicare billing

Part B allowed, 2024
$347,503
Medicare patients
309
Services billed
9,493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in North Massapequa

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →